SHSCX Holdings — BlackRock Health Sciences Opportunities Portfolio
All 152 reported holdings of BlackRock Health Sciences Opportunities Portfolio (SHSCX) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Eli Lilly & Company | 12.29% | $725.60M |
| Johnson & Johnson | 8.77% | $518.08M |
| Unitedhealth Group, Inc. | 6.10% | $360.31M |
| Merck & Company, Inc. | 4.94% | $291.63M |
| Gilead Sciences, Inc. | 4.19% | $247.53M |
| Abbvie, Inc. | 3.94% | $232.53M |
| Amgen, Inc. | 3.37% | $198.77M |
| Thermo Fisher Scientific, Inc. | 3.02% | $178.45M |
| Vertex Pharmaceuticals, Inc. | 2.74% | $161.97M |
| Pfizer, Inc. | 2.61% | $154.44M |
| Edwards Lifesciences Corp. | 2.51% | $147.95M |
| Danaher Corp. | 2.00% | $117.85M |
| Abbott Laboratories | 1.97% | $116.58M |
| Intuitive Surgical, Inc. | 1.95% | $115.26M |
| Teva Pharmaceutical Industries Ltd. | 1.87% | $110.25M |
| Boston Scientific Corp. | 1.59% | $93.96M |
| Elevance Health, Inc. | 1.56% | $92.38M |
| Argenx SE | 1.26% | $74.40M |
| Biogen, Inc. | 1.21% | $71.38M |
| Astrazeneca PLC | 1.21% | $71.36M |
| Stryker Corp. | 1.15% | $67.71M |
| Blackrock Funds Iii | 1.01% | $59.51M |
| Revolution Medicines, Inc. | 0.96% | $56.90M |
| Humana, Inc. | 0.92% | $54.43M |
| Regeneron Pharmaceuticals, Inc. | 0.91% | $53.89M |
| Bristol-Myers Squibb Company | 0.89% | $52.44M |
| Cogent Biosciences, Inc. | 0.83% | $49.18M |
| Dexcom, Inc. | 0.83% | $48.95M |
| Waters Corp. | 0.81% | $47.73M |
| Cytokinetics, Inc. | 0.75% | $44.15M |
| Penumbra, Inc. | 0.72% | $42.40M |
| Hca Healthcare, Inc. | 0.72% | $42.26M |
| Insmed, Inc. | 0.71% | $41.92M |
| Cvs Health Corp. | 0.71% | $41.82M |
| Rhythm Pharmaceuticals, Inc. | 0.70% | $41.62M |
| Galderma Group AG | 0.67% | $39.79M |
| Incyte Corp. | 0.65% | $38.33M |
| Novartis AG | 0.64% | $37.79M |
| Protagonist Therapeutics, Inc. | 0.62% | $36.88M |
| Agilent Technologies, Inc. | 0.62% | $36.76M |
| Idexx Laboratories, Inc. | 0.62% | $36.69M |
| Nuvalent, Inc. | 0.59% | $34.87M |
| United Therapeutics Corp. | 0.53% | $31.01M |
| Alnylam Pharmaceuticals, Inc. | 0.49% | $28.66M |
| Bruker Corp. | 0.47% | $27.79M |
| Moderna, Inc. | 0.45% | $26.46M |
| Iqvia Holdings, Inc. | 0.44% | $25.73M |
| Illumina, Inc. | 0.40% | $23.78M |
| Medline, Inc. | 0.37% | $22.12M |
| Apogee Therapeutics, Inc. | 0.37% | $21.66M |
| Blackrock Liquidity Funds | 0.36% | $21.27M |
| Mckesson Corp. | 0.35% | $20.48M |
| Biomarin Pharmaceutical, Inc. | 0.31% | $18.48M |
| Neurocrine Biosciences, Inc. | 0.30% | $17.89M |
| Dianthus Therapeutics, Inc. | 0.29% | $17.34M |
| Roivant Sciences Ltd. | 0.29% | $16.91M |
| Quest Diagnostics, Inc. | 0.28% | $16.60M |
| Lb Pharmaceuticals, Inc. | 0.27% | $15.88M |
| Ucb SA | 0.27% | $15.73M |
| Oruka Therapeutics, Inc. | 0.26% | $15.50M |
| Stoke Therapeutics, Inc. | 0.25% | $14.63M |
| Arcus Biosciences, Inc. | 0.25% | $14.51M |
| Madrigal Pharmaceuticals, Inc. | 0.23% | $13.72M |
| Ionis Pharmaceuticals, Inc. | 0.22% | $13.01M |
| Cencora, Inc. | 0.21% | $12.47M |
| Exelixis, Inc. | 0.20% | $11.69M |
| Elanco Animal Health, Inc. | 0.20% | $11.53M |
| Daiichi Sankyo Company Ltd. | 0.19% | $11.34M |
| Scholar Rock Holding Corp. | 0.19% | $11.15M |
| Adarx Pharmaceuticals, Inc. | 0.18% | $10.89M |
| Kailera Therapeutics, Inc. | 0.18% | $10.65M |
| West Pharmaceutical Services, Inc. | 0.18% | $10.50M |
| Mbx Biosciences, Inc. | 0.18% | $10.49M |
| Natera, Inc. | 0.17% | $10.32M |
| Charles River Laboratories International, Inc. | 0.17% | $10.15M |
| Bio-Techne Corp. | 0.17% | $10.02M |
| Kailera Therapeutics, Inc. | 0.17% | $9.82M |
| Novocure Ltd. | 0.17% | $9.79M |
| Kartos Therapeutics, Inc. | 0.16% | $9.54M |
| Intellia Therapeutics, Inc. | 0.16% | $9.35M |
| Erasca, Inc. | 0.15% | $9.11M |
| Viridian Therapeutics, Inc. | 0.15% | $9.09M |
| Glaukos Corp. | 0.15% | $9.01M |
| Axsome Therapeutics, Inc. | 0.15% | $8.95M |
| Bright Minds Biosciences, Inc. | 0.14% | $8.42M |
| Agios Pharmaceuticals, Inc. | 0.14% | $7.99M |
| Eikon Therapeutics, Inc. | 0.13% | $7.83M |
| Vaxcyte, Inc. | 0.13% | $7.57M |
| Laronde, Inc. | 0.13% | $7.47M |
| Mettler-Toledo International, Inc. | 0.12% | $7.15M |
| Angitia Biopharmaceuticals Limited | 0.11% | $6.52M |
| Enanta Pharmaceuticals, Inc. | 0.11% | $6.47M |
| Alumis, Inc. | 0.11% | $6.34M |
| Immunome, Inc. | 0.11% | $6.30M |
| Monte Rosa Therapeutics, Inc. | 0.11% | $6.27M |
| Genesis Therapeutics, Inc. | 0.10% | $6.09M |
| Bridgebio Oncology Therapeutics, Inc. | 0.10% | $6.04M |
| Palvella Therapeutics, Inc. | 0.10% | $6.01M |
| Radnet, Inc. | 0.10% | $6.00M |
| Bridgebio Pharma, Inc. | 0.10% | $5.76M |
| Kalvista Pharmaceuticals, Inc. | 0.10% | $5.71M |
| Beam Therapeutics, Inc. | 0.09% | $5.53M |
| Aktis Oncology, Inc. | 0.09% | $5.53M |
| Immunocore Holdings PLC | 0.09% | $5.45M |
| Dyne Therapeutics, Inc. | 0.09% | $5.39M |
| Denali Therapeutics, Inc. | 0.09% | $5.30M |
| Maze Therapeutics, Inc. | 0.08% | $4.88M |
| Summit Therapeutics, Inc. | 0.08% | $4.86M |
| Relay Therapeutics, Inc. | 0.08% | $4.82M |
| Avalo Therapeutics, Inc. | 0.08% | $4.78M |
| Kodiak Sciences, Inc. | 0.08% | $4.72M |
| Kymera Therapeutics, Inc. | 0.07% | $4.41M |
| Alcon AG | 0.07% | $4.35M |
| Sagimet Biosciences, Inc. | 0.07% | $4.27M |
| Biontech SE | 0.07% | $4.02M |
| Insitro, Inc. | 0.07% | $3.96M |
| Biohaven Ltd. | 0.07% | $3.84M |
| Zealand Pharma A/s | 0.06% | $3.75M |
| Ptc Therapeutics, Inc. | 0.06% | $3.62M |
| Bicara Therapeutics, Inc. | 0.06% | $3.48M |
| Quanta Dialysis Technologies Ltd. | 0.06% | $3.45M |
| Ultragenyx Pharmaceutical, Inc. | 0.05% | $3.13M |
| Moonlake Immunotherapeutics | 0.05% | $3.10M |
| Upstream Bio, Inc. | 0.05% | $2.86M |
| Allogene Therapeutics, Inc. | 0.04% | $2.62M |
| Eyepoint, Inc. | 0.04% | $2.53M |
| Ocular Therapeutix, Inc. | 0.04% | $2.33M |
| Wave Life Sciences Ltd. | 0.04% | $2.28M |
| Definium Therapeutics, Inc. | 0.03% | $1.97M |
| Bridgebio Oncology Therapeutics, Inc. | 0.03% | $1.88M |
| Vor Biopharma, Inc. | 0.03% | $1.72M |
| Regenxbio, Inc. | 0.03% | $1.50M |
| Maplight Therapeutics, Inc. | 0.02% | $1.47M |
| Corvus Pharmaceuticals, Inc. | 0.02% | $1.37M |
| 4d Molecular Therapeutics, Inc. | 0.02% | $1.25M |
| Syndax Pharmaceuticals, Inc. | 0.02% | $1.15M |
| Annexon, Inc. | 0.02% | $1.02M |
| Nyxoah SA | 0.02% | $1.01M |
| Goldfinch Bio, Inc. | 0.02% | $934.61K |
| Orchestra Biomed Holdings, Inc. | 0.01% | $805.97K |
| Exo Imaging, Inc. | 0.01% | $666.31K |
| Cellarity, Inc. | 0.01% | $497.83K |
| Affinivax, Inc. | 0.01% | $449.54K |
| Abiomed, Inc. | 0.01% | $367.90K |
| Blueprint Medicines Corp. | 0.00% | $202.86K |
| Mirati Therapeutics, Inc. | 0.00% | $180.52K |
| Gossamer Bio, Inc. | 0.00% | $84.32K |
| Swift Health Systems, Inc. | 0.00% | $3.79K |
| Arcellx, Inc. | 0.00% | $6.51K |
| Hologic, Inc. | 0.00% | $1.38K |
| Goldfinch Equity Warrants | 0.00% | $4 |
| Frequency Therapeutics Cvr | 0.00% | $4 |
SHSCX overview: performance, fees, allocation and SEC filings